This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Epigenetic editing startup Chroma Medicine is merging ...

Nvelop Therapeutics has launched to improve gene therapy delivery. The company was first founded in 2022 with $100 million in funding from investors on the basis of independently developed platforms ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Two prominent gene-editing startups, Chroma ...

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio. nChroma will develop Chroma’s epigenetic editing platform and Nvelop’s viruslike delivery platform. The new firm has raised $75 ...

A $100-million startup emerging from stealth is developing not one but two answers to the challenge that has long dogged the gene therapy field: How can genetic medicines best be delivered to patients ...

Two biotech companies, Chroma Medicine and Nvelop Therapeutics, have merged to form nChroma Bio, a new company that combines epigenetic editing capabilities with in vivo delivery technologies.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nvelop Therapeutics, a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced that it will ...

Chroma Medicine and Nvelop Therapeutics merge to bring together best-in-class epigenetic editing technologies and next generation in vivo delivery technologies to unlock the full potential of genetic ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Jeff Walsh, the newly formed ...